Skip to main content

Treatment of reperfusion injury using a mitochondrial targeted approach: towards a better understanding of the disease

Objective

Current interventional treatment of acute myocardial infarction (AMI) focused on re-establishing cardiac reperfusion has significantly improved clinical outcome by reducing infarct size and mortality due to cardiac ischemia.It is now recognized that events triggered at reperfusion also result in cell death and may account for as much as 50% of the infarct volume, this being termed ischemia-reperfusion injury (IRI). Mitochondrial permeability transition pore (mPTP) opening appears to be a responsible for IRI and a recent small clinical trial with cyclosporine A shows that it is a feasible target for the development of new therapies to treat it. Since total infarct size is a major determinant of a patients risk to develop heart failure, treating IRI is expected to further reduce morbidity, mortality and the need for regenerative medicine following cardiac ischemia. By harnessing a multi-disciplinary consortium of clinical and basic scientists along with four SMEs, MitoCare brings state-of-the art expertise together to 1) better understand IRI pathophysiology and factors directly or indirectly influencing patient’s recovery or response to treatment; 2) investigate the translational usefulness of preclinical models; and 3) compare selected treatments. These objectives will be reached through the following work plan: A) a medium-scale phase II clinical study will evaluate the efficacy of a novel complementary therapy to PCI, the new mPTP modulator TRO40303, while at the same time 1) perform extensive sampling from subjects in the study for analysis of standard and emerging biomarkers; 2) identify confounding factors influencing patients’ outcomes. B) Parallel investigations in preclinical in vitro and in vivo AMI models. C) Statistical analysis of data from clinical and preclinical studies, to identify better diagnostic and prognostic endpoints in man and assess predictive utility of preclinical models.

Call for proposal

FP7-HEALTH-2010-single-stage
See other projects for this call

Coordinator

TROPHOS SA
Address
Parc Scientifique Luminy Case 931
13288 Marseille Cedex 9
France

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Julien Veys (Mr.)
EU contribution
€ 2 199 952

Participants (16)

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France
EU contribution
€ 536 624
Address
3 Avenue Victoria
75000 Paris

See on map

Activity type
Research Organisations
Administrative Contact
Anne Skrobot (Ms.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 278 988
Address
Rue De Tolbiac 101
75654 Paris

See on map

Activity type
Research Organisations
Administrative Contact
Didier Lemoine (Mr.)
UNIVERSITETET I BERGEN
Norway
EU contribution
€ 212 512
Address
Museplassen 1
5020 Bergen

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Inger Gjesdahl (Ms.)
REGION NORDJYLLAND (NORTH DENMARK REGION)
Denmark
EU contribution
€ 258 276
Address
Niels Bohrs Vej 30
9220 Aalborg

See on map

Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Svend Eggert Jensen (Dr.)
MAX IV Laboratory, Lund University
Sweden
EU contribution
€ 413 120
Address
Paradisgatan 5c
22100 Lund

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
David Erlinge (Prof.)
REGION HOVEDSTADEN
Denmark
EU contribution
€ 35 184
Address
Kongens Vaenge 2
3400 Hillerod

See on map

Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Skov Jensen Jan (Prof.)
KAROLINSKA INSTITUTET

Participation ended

Sweden
EU contribution
€ 10 068,11
Address
Nobels Vag 5
17177 Stockholm

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Caroline Hamilton (Ms.)
UNIVERSITY OF BRISTOL
United Kingdom
EU contribution
€ 272 064
Address
Beacon House Queens Road
BS8 1QU Bristol

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Johanna Rule (Ms.)
FIRALIS
France
EU contribution
€ 778 321
Address
Rue Du Fort 35
68330 Huningue

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Fuat Firat (Mr.)
GOETEBORGS UNIVERSITET

Participation ended

Sweden
Address
Vasaparken
405 30 Goeteborg

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Emilia Rung (Dr.)
IMACOR AB
Sweden
EU contribution
€ 299 460
Address
Rektorsvagen 16
55467 Lund

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Hakan Arheden (Prof.)
MOBILE HEALTH SAS
France
EU contribution
€ 113 525,89
Address
Avenue Kleber 112
75116 Paris

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Gilles Sonou (Mr.)
OSLO UNIVERSITETSSYKEHUS HF
Norway
EU contribution
€ 201 530
Address
Kirkeveien 166 Tarnbygget
0450 Oslo

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Dag Kvale (Dr.)
ODENSE UNIVERSITETSHOSPITAL
Denmark
EU contribution
€ 206 608
Address
Sdr. Boulevard 29
5000 Odense

See on map

Activity type
Research Organisations
Administrative Contact
Henrik Steen Hansen (Dr.)
HELSE STAVANGER HF
Norway
EU contribution
€ 101 052
Address
Gerd Ragna Bloch Thorsens Gate 8
4011 Stavanger

See on map

Activity type
Other
Administrative Contact
Torbjørn Aarsland (Mr.)
CENTRE HOSPITALIER REGIONAL DE MARSEILLE ASSISTANCE PUBLIQUE-HOPITAUX MARSEILLE
France
EU contribution
€ 73 674
Address
Rue Brochier 80
13354 Marseille Cedex 20

See on map

Activity type
Research Organisations
Administrative Contact
Isabelle Amabile (Ms.)